0001209191-23-050222.txt : 20230920 0001209191-23-050222.hdr.sgml : 20230920 20230920200824 ACCESSION NUMBER: 0001209191-23-050222 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230918 FILED AS OF DATE: 20230920 DATE AS OF CHANGE: 20230920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CHESS ROBERT CENTRAL INDEX KEY: 0001227886 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 231267578 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-18 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001227886 CHESS ROBERT C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 1 0 0 0 1 Common Stock 2022-09-22 4 S 0 10200 0.67 D 274773 D Common Stock 2100 I by daughter Common Stock 2100 I by son Common Stock 2100 I by daughter Stock Option 0.68 2023-09-19 4 A 0 85000 0.00 A 2031-09-18 Common Stock 85000 85000 D This transaction was made pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $0.66 to $0.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Includes 56,794 shares previously reported as shares held in Grantor Retained Annuity Trusts for which the reporting person was the sole trustee. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. This stock option vests in equal monthly installments over the one-year period beginning on September 19, 2023. Mark A. Wilson, Attorney-in-Fact 2023-09-20